Matthias Müllenbeck: What if we paid doctors to keep people healthy?
Matthias Müllenbeck: Što ako bismo plaćali liječnicima da održe ljude zdravima?
As the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology. Full bio
Double-click the English transcript below to play the video.
fell off the evening before.
I'm sitting in a dentist's chair.
sjedim u zubarskoj stolici.
so that I can get rid of my pain,
tako da me prestane boljeti,
of a titanium implant surgery.
ugradnje titanskih implantata.
a damaged tooth
may add up to 10,000 US dollars.
može doseći do 10.000 US dolara.
that could be earned with me
koji bi mogao zaraditi na meni
for my dentist?
wasn't an isolated case.
estimated that in the United States,
je procijenilo da je u SAD-u
surgical procedures --
and pacemaker implantations,
options had not been fully exploited
nisu bili do kraja iskorišteni
in other countries,
u drugim zemljama,
idete liječniku u SAD-u,
if you go to a doctor in the US,
to be subjected to a surgical intervention
vam se nuditi operacija,
an immediate need for it.
to run such unnecessary procedures?
na nepotrebne operacije?
health care systems themselves
sam zdravstveni sustav
certain procedures or treatments.
određenih postupaka ili tretmana.
reimburse practitioners
nagrađuje liječnike
of treatments performed,
izvedenih zahvata,
that tempts some practitioners
dovodi u napast neke liječnike
surgical treatments
kirurške tretmane,
other treatment options.
started to implement
kvaliteti i učinkovitosti,
health care systems' architecture
zdravstvenom sustavu
of a disease in the first place
sprečavaju pojavu bolesti
applied to a patient
primjenjivati na pacijentu,
system's architecture --
of the incentive structure.
u strukturi naknada.
for keeping their customers healthy
održavaju svoje pacijente zdravima,
once people are already sick.
kada se ljudi razbole.
that largely cares for the sick,
najviše brine za bolesne,
people once they have become sick
od liječenja ljudi kada postanu bolesni,
before they get sick.
prije nego oboli.
of all those involved --
fokus svih sudionika,
to pharmaceutical and medical companies --
farmaceutskih i medicinskih kompanija,
ultimately sells:
zapravo prodaje:
reimburse practitioners
performed on a patient
individual is kept healthy
pojedinac ostao zdrav
to an insurance company
naknadu osiguravajućem društvu
is kept healthy
pojedinac ostao zdrav
of acute medical intervention.
hitna medicinska intervencija.
any further monetary compensation
dobiti novčanu nadoknadu
to treat the disease of that individual,
potrebna za liječenje bolesti,
for every evidence-based treatment option
dokazano potreban tretman,
will be paid again.
their customers healthy,
svojih klijenata zdravima
any unnecessary medical interventions
medicinske intervencije,
that eventually become sick.
broj ljudi koji obolijevaju.
to treat the sick will be,
for all parties being involved
svih uključenih strana
structure shifts, now,
health care system
zdravstvenog sustava
and singular treatment options,
to stay healthy and live long.
to share their health data
dijeliti svoje zdravstvene podatke
understands early enough
razumio dovoljno rano
to their health is needed.
po pitanju njihovog zdravlja.
podataka za životnog vijeka,
cardiometabolic profiling
kardio-metaboličko profiliranje
and general practitioners,
i liječnicima opće prakse,
and their physical activity --
lijekove i fizičku aktivnost,
individual high-risk disease.
za koju postoji visoki rizik.
na umjetnoj inteligenciji
data analysis
of sensor technologies
of the individual health status possible.
zdravstveni status pojednica.
by devices like this
parametara uređajima kao što je ovaj,
tumor DNA in your bloodstream
tumorske DNA u vašem krvotoku
for such monitoring technologies.
in certain oncological diseases
kod nekih onkoloških bolesti
is diagnosed too late
su dijagnoze postavljene prekasno
that could potentially have cured them
lijekovi i tretmani
been detected earlier.
based on a few milliliters of blood,
na temelju nekoliko mililitara krvi,
of circulating tumor DNA
cirkulirajuće tumorske DNA
detection can have
dijagnosticiranje može imati,
for non-small cell lung cancer
za rak pluća ne-malih stanica,
which is early, is 49 percent.
što je vrlo rano, iznosi 49 posto.
at stage four, which is late,
u četvrtoj fazi, što je kasno,
to prevent a large number of deaths
for circulating tumor DNA
na cirkulirajuću tumorsku DNA,
u bolesti koje se mogu nadzirati,
a manageable disease,
can likely be increased.
će vrlo vjerojatno biti veći.
had a single chronic disease,
imalo neku kroničnu bolest,
of the $3 trillion US health care budget
zdravstvenog budžeta od 3 trilijuna dolara
such chronic diseases.
takvih kroničnih bolesti.
to reduce this 86 percent,
da se tih 86 posto smanji,
not reacted and changed already?
već nisu reagirali i promijenili se?
is a sick care system
bolesnog sustava
that focuses on prevention
čiji je fokus na prevenciji
in the system to change.
u sustavu da se mijenja.
to shift budgets and policies
promjenama u budžetu i pravilima,
and non-financial incentives.
financijski i nefinancijski poticaji.
a regulatory framework
of personal health data
osobnih zdravstvenih podataka
stringent and sensible.
farmaceutskih i medicinskih kompanija
pharmaceutical and medical companies
and, most important,
što je najvažnije,
the willingness and motivation
bez volje i motivacije pojedinaca
in a sustained way,
u održiv način,
the health data on a constant basis.
zdravstvenih podataka na dnevnoj bazi.
within the health care industry today
zdravstvenoj industriji
more diseases in the first place
spriječiti više bolesti,
the onset of certain preventable diseases
nekih bolesti koje se mogu izbjeći,
and healthier lives for more people.
i zdravijem životu ljudi.
that we need to initiate that change
za tu promjenu potrebne
ABOUT THE SPEAKER
Matthias Müllenbeck - Business developerAs the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology.
Why you should listen
Throughout his career in various roles at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck worked on strategic asset, technology and diagnostic-licensing deals and on bringing to market innovative chemical products. He holds a PhD in immunology from the Humboldt University in Berlin and has worked at the Max-Planck Institute for infection biology in Berlin, at Bayer, and at the Albert-Schweizer Hospital in Lambarané, Gabon.
Matthias Müllenbeck | Speaker | TED.com